A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma. Liu Z, Wu Q, Li W, Li P, et al. Lung Cancer 2023;186:107386.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu Z, Wu Q, Li W, Li P, et al. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma. Lung Cancer 2023;186:107386.
PMID: 37922771